-Rejection of an allogeneic bone marrow graft following successful treatment of severe graft-versus-host disease (GVHD).
A 38-year-old female with acute myelogenous leukemia (M2) received an allogeneic bone marrow graft from an HLA-DR one locus-mismatched sister during the first remission. The conditioning regimen consisted of busulfan and cyclophosphamide. Acute graft-versus-host disease (GVHD) developed on day 11 after transplantation. Although the GVHD was successfully treated with methylprednisolone, peripheral blood neutrophils that had begun to increase disappeared in association with improvement of the GVHD and graft rejection was eventually diagnosed. The second bone marrow transplantation from the same donor ended up with engraftment failure. She died of sepsis due to Candida albicans following the development of Epstein-Barr virus-associated B-lymphoproliferative disorder. The clinical course of this patient indicates that successful therapy of severe GVHD with methylprednisolone may lead to marrow graft rejection.
Sugimori
N
N
Third Department of Medicine, Kanazawa University School of Medicine.
Nakao
S
S
Takamatsu
H
H
Takami
A
A
Ueda
M
M
Shiobara
S
S
Matsuda
T
T
D000208:Acute Disease; D000328:Adult; D000893:Anti-Inflammatory Agents / Q000009:adverse effects; D016026:Bone Marrow Transplantation; D005260:Female; D006084:Graft Rejection / Q000139:chemically induced*; D006086:Graft vs Host Disease / Q000188:drug therapy*; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000628:therapy; D008775:Methylprednisolone / Q000009:adverse effects
D000893:Anti-Inflammatory Agents; D008775:Methylprednisolone